摘要
目的评价不同厂家替硝唑片的相对生物利用度和生物等效性。方法18名男性健康受试者采用随机、自身对照、交叉试验方法,单剂量口服不同厂家的替硝唑片后,用RP-HPLC法测定血浆中替硝唑质量浓度。结果单剂量口服替硝唑1 000 mg受试和参比制剂的达峰时间tmax分别为(1.72±0.45)和(1.97±0.66)h;血药浓度峰值Cmax分别为(21.39±3.36)和(20.56±2.98)μg.mL-1;t1/2分别为(17.83±2.24)和(17.71±2.65)h;Ke分别为(0.039±0.005)和(0.04±0.006)h-1;药时曲线下面积AUC(0→t)分别为(502.56±83.83)和(505.48±84.91)μg.h.mL-1。两种片剂的药物动力学参数均无显著性差异(P>0.05),受试制剂的相对生物利用度(F)为99.42%。结论两种制剂生物等效。
Objective To evaluate the relative bioavailability and bioequivalence of tset tinidazole tablets. Methods 18 male healthy volunteers orally took a single dose of 1 000 mg tablets of test and reference in randamized self-crossover ways. The plasma concentrations of tinidazole determined by RP-HPLC with UV detector. Results The pharmacokinetic parameters of reference and test drugs were as follow; tmax (1.72±0.45)and (1.97±0. 66) h;Cmax(21. 39±3. 36) and(20.56±2.98) μg· mL^-1 ;t1/2 (17. 83±2. 24) and(17.71±2.65) h; Ke (0.039±0.005) and (0.04±0. 006) h^-1 ; AUC(0→t) (502.56±83.83)and (505.48±84.91) μg· h · mL^-1 , respectively . There was no statistical difference between test and reference tinidazole tablets in pharmacokinetic parameters(P〉0. 05). The relative bioavailability of tinidazole tablets was 99.42%. Conclusion Two preparations of tinidazole tablet are bioequivalent.
出处
《西北药学杂志》
CAS
2006年第4期163-165,共3页
Northwest Pharmaceutical Journal